← All news
Markets

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

1 source ·1 article ·Sep 23, 12:20 UTC Viking

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Covered by 1 outlet

All coverage · 1 article